FirmaIQ
Org.nr 927 648 946 2023 → 2024 Year-over-year analysis

AGIANA PHARMACEUTICALS AS: årsregnskap 2024 vs 2023

Grew 127% on revenue, weaker earnings, fresh owner capital

approved 2025-03-27; registry 2025-07-14; journal 2025 668474

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2024 with 2023 for AGIANA PHARMACEUTICALS AS. Revenue 235.3k NOK → 534.6k NOK (+127.2%). Net result -2.95m NOK → -4.50m NOK. Equity -5.88m NOK → 13.42m NOK.

On the constructive side: revenue rose; equity strengthened; cash rose. Pressures included: operating result weakened; net result weakened.

Also worth watching: payroll increased. All figures are taken from the published annual accounts for AGIANA PHARMACEUTICALS AS.

At a glance

Scorecard

Revenue
235.3k NOK 534.6k NOK
+127.2%
Operating result
-2.64m NOK -4.66m NOK
-76.8%
Net result
-2.95m NOK -4.50m NOK
-52.8%
Equity
-5.88m NOK 13.42m NOK
+328.4%
Cash
1.44m NOK 13.62m NOK
+844.3%
Total assets
1.68m NOK 14.14m NOK
+741.3%

What improved

  • ↑

    Revenue rose

    Operating income / revenue moved from 235.3k NOK to 534.6k NOK (+127.2% YoY). Calculated

  • ↑

    Equity strengthened

    Book equity -5.88m NOK → 13.42m NOK (equity ratio -349.5% → 94.9%). Calculated

  • ↑

    Cash rose

    Bank deposits 1.44m NOK → 13.62m NOK (+844.3% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 30.0k NOK → 23.82m NOK (+23.79m NOK). Reported fact

What deteriorated

  • ↓

    Operating result weakened

    Operating result -2.64m NOK → -4.66m NOK (op. margin -1120.3% → -871.7%). Calculated

  • ↓

    Net result weakened

    Net result -2.95m NOK → -4.50m NOK (net margin -1252.4% → -842.0%). Calculated

Things to notice

  • ·

    Payroll increased

    Salary cost 2.50m NOK → 3.34m NOK (1061% → 625% of revenue). Calculated